Back to Search
Start Over
Supplemental Table from MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplemental Table 1. Post-discontinuation therapies
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....a9935dfa4ebd65bb05f8542cd874cec7
- Full Text :
- https://doi.org/10.1158/1078-0432.22468389